[4] Chioua M., Buzzi E., Moraleda I., Iriepa I., Maj M., Wnorowski A., Giovannini C., Tramarin A., Portali F., Ismaili L., López-Alvarado P.,
Tacripyrimidines, the First Tacrine-Dihydropyrimidine Hybrids, as Multi-Target-Directed Ligands for Alzheimer's Disease:
European Journal of Medicinal Chemistry,
155: 839-846 (2018).
[5] Majellaro M., Jespers W., Crespo A., Núñez M.J., Novio S., Azuaje J., Prieto-Díaz R., Gioé C., Alispahic B., Brea J., Loza M.I.,
3, 4-Dihydropyrimidin-2 (1 H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure–Activity Relationship Studies, and Enantiospecific Recognition,
Journal of Medicinal Chemistry,
64(1): 458-480 (2020).
[10] Tokdemir Öztürk S., Aksu P., Turan N., Buldurun K., Tanış E., Çolak N.,
Preparation, Spectral Characterization, ESR Measurements and DFT Calculations of Schiff Base Copper (II) Complex,
Inorganic and Nano-Metal Chemistry,
51(11): 1546-1552 (2021).
[14] Turan N., Tanış E., Buldurun K., Çolak N.,
Synthesis, Structure, DFT Calculations, and in Silico Toxic Potential of Ni (II), Zn (II), and Fe (II) Complexes with a Tridentate Schiff Base,
Russian Journal of General Chemistry,
91(8): 1572-1577 (2021).
[21] Dong J, Zhang Q, Wang Z, Huang G, Li S Recent Advances in the Development of Indazole-Based Anticancer Agents. Chem. Med. Chem., 13(15):1490-1507 (2018).